An oral norovirus vaccine generates mucosal immunity and reduces viral shedding in a phase 2 placebo-controlled challenge study flitter2025oral
Phase 2b randomized, placebo-controlled vaccination and human challenge study of an oral tablet norovirus vaccine (VXA-G1.1-NN) assessing immunogenicity and efficacy against norovirus GI.1 challenge, including quantification of viral shedding in stool and emesis over post-challenge days. This extraction includes individual participant stool and emesis shedding measurements from provided figure-derived CSV rows for placebo recipients.
Analytes
emesis
Norovirus shedding measurement in emesis, from figure-derived CSV data (quantitative values and negatives). Assay/method details not provided in the supplied text/CSV excerpt.
Measurements only — no shedding model is fitted to this analyte, usually because it is sampled once per participant, leaving no trajectory to fit, or because nothing was ever detected. Open triangles are non-detects, drawn at the assay's censoring limit. See the modelling methods for what these estimates do and do not support.
stool
Norovirus shedding measurement in stool, from figure-derived CSV data (quantitative values and negatives). Assay/method details not provided in the supplied text/CSV excerpt.
Fitted by censored maximum likelihood. The red line is the median individual; the shaded region is the full range of a simulated cohort drawn from the fitted population, so it shows what simulating from this dataset would produce rather than a confidence interval, with dashed lines at the central 95%. Open triangles are non-detects, drawn at the censoring limit and entering the fit as "below this value" rather than being dropped. See the modelling methods for what these estimates do and do not support.